232 related articles for article (PubMed ID: 35641216)
1. Rational Second-Generation Antiandrogen Use in Prostate Cancer.
Orme JJ; Pagliaro LC; Quevedo JF; Park SS; Costello BA
Oncologist; 2022 Mar; 27(2):110-124. PubMed ID: 35641216
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
3. An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer.
Mitsogianni M; Papatsoris A; Bala VM; Issa H; Moussa M; Mitsogiannis I
Expert Opin Pharmacother; 2023; 24(16):1765-1774. PubMed ID: 37545430
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives.
Pinto F; Dibitetto F; Ragonese M; Bassi P
Med Sci (Basel); 2022 Apr; 10(2):. PubMed ID: 35645241
[TBL] [Abstract][Full Text] [Related]
5. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer.
Rice MA; Malhotra SV; Stoyanova T
Front Oncol; 2019; 9():801. PubMed ID: 31555580
[TBL] [Abstract][Full Text] [Related]
6. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
[TBL] [Abstract][Full Text] [Related]
7. Safety of antiandrogen therapy for treating prostate cancer.
Ricci F; Buzzatti G; Rubagotti A; Boccardo F
Expert Opin Drug Saf; 2014 Nov; 13(11):1483-99. PubMed ID: 25270521
[TBL] [Abstract][Full Text] [Related]
8. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
BJU Int; 2015 Jul; 116(1):30-6. PubMed ID: 25523493
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
Gillatt D
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S17-26. PubMed ID: 16845534
[TBL] [Abstract][Full Text] [Related]
10. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies.
Dan TD; Eldredge-Hindy HB; Hoffman-Censits J; Lin J; Kelly WK; Gomella LG; Lallas CD; Trabulsi EJ; Hurwitz MD; Dicker AP; Den RB
Am J Clin Oncol; 2017 Aug; 40(4):342-347. PubMed ID: 25723740
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of maintenance of the common androgen deprivation therapy with the new antiandrogen therapy in patients with castration-resistant prostate cancer: a systematic review.
Salgado CM; Garcia-Perdomo HA; Reis LO
Int Urol Nephrol; 2022 Jun; 54(6):1187-1192. PubMed ID: 35384583
[TBL] [Abstract][Full Text] [Related]
12. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
Molecules; 2020 May; 25(10):. PubMed ID: 32456317
[TBL] [Abstract][Full Text] [Related]
13. [Management of enzalutamide, a new hormonal therapy].
Beuzeboc P; Benderra MA; de La Motte Rouge T
Bull Cancer; 2014 Jan; 101(1):107-12. PubMed ID: 24491670
[TBL] [Abstract][Full Text] [Related]
14. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
15. Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide.
Shiota M; Machidori A; Abe T; Monji K; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Yokomizo A; Naito S; Eto M
Int J Urol; 2020 Dec; 27(12):1109-1115. PubMed ID: 32929792
[TBL] [Abstract][Full Text] [Related]
16. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Int J Clin Oncol; 2019 Jul; 24(7):842-847. PubMed ID: 30739263
[TBL] [Abstract][Full Text] [Related]
18. Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer.
Pyrgidis N; Vakalopoulos I; Sountoulides P
Hormones (Athens); 2021 Mar; 20(1):73-84. PubMed ID: 33140306
[TBL] [Abstract][Full Text] [Related]
19. Overcoming mutation-based resistance to antiandrogens with rational drug design.
Balbas MD; Evans MJ; Hosfield DJ; Wongvipat J; Arora VK; Watson PA; Chen Y; Greene GL; Shen Y; Sawyers CL
Elife; 2013 Apr; 2():e00499. PubMed ID: 23580326
[TBL] [Abstract][Full Text] [Related]
20. Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies.
Rice MA; Hsu EC; Aslan M; Ghoochani A; Su A; Stoyanova T
Mol Cancer Ther; 2019 Jul; 18(7):1230-1242. PubMed ID: 31028097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
